Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: Gastroenterology. 2022 Nov 17;164(3):439–453. doi: 10.1053/j.gastro.2022.11.019

Figure 6. KCTD17 expression tracks with hepatic ChREBP activity and NAFLD severity in patients.

Figure 6.

(A and B) KCTD17 expression in patients as related to NAS (p=0.004) (A) or NAFLD-induced liver fibrosis (B). Each dot represents hepatic KCTD17 expression in one subject. (C) KCTD17, lipogenic and glycolytic gene expression in patients with NAFLD/NASH as compared with healthy controls. (D) Correlation between KCTD17 and PKLR, as well as key lipogenic genes. Correlogram represents the value of Spearman's correlation coefficient rho. The intensity of color and the size of circle indicates Spearman's rho. *P < 0.05, **P < 0.01, ****P < 0.0001; p-values calculated using Kruskal–Wallis test or one-tailed Wilcoxon rank sum test.